Novo Nordisk Strikes Major Deal with Deep Apple Therapeutics for Oral Cardiometabolic Medicines

Novo Nordisk has entered a research collaboration and exclusive worldwide license agreement with Deep Apple Therapeutics to develop oral small molecule therapeutics targeting cardiometabolic diseases, including obesity25.

The partnership aims to discover first-in-class, oral medicines focused on a novel non-incretin GPCR target, leveraging Deep Apple's machine-learning-powered drug discovery and cryo-EM technology25.

Deep Apple Therapeutics will receive up to $812 million in upfront, research, and milestone payments, along with potential royalties on commercialized products235.

Novo Nordisk will have exclusive global rights to develop, manufacture, and commercialize any resulting compounds, with a transition of programs prior to IND-enabling studies25.

Sources:

2. https://www.prnewswire.com/news-releases/deep-apple-therapeutics-announces-collaboration-with-novo-nordisk-to-discover-and-develop-oral-therapeutics-for-cardiometabolic-diseases-302478417.html

3. https://www.contractpharma.com/breaking-news/novo-nordisk-signs-800m-deal-with-deep-apple-therapeutics-for-obesity-rd/

5. https://www.prnewswire.com/news-releases/deep-apple-therapeutics-announces-collaboration-with-novo-nordisk-to-discover-and-develop-oral-therapeutics-for-cardiometabolic-diseases-302478547.html